In addition, another developmental transcription factor, HNF1A, is a novel regulator of pancreatic cancer stem cell properties, and HNF1A + tumors (non-QM, overlap with the exocrine/ADEX subtype) benefit more from FOLFIRINOX than gemcitabine-based treatment [87]. This evidence concerns the gene HNF1A and familial pancreatic carcinoma.